A multistate tuberculosis pharmacometric model: a framework for studying anti-tubercular drug effects in vitro
暂无分享,去创建一个
Ulrika S H Simonsson | Yanmin Hu | A. Coates | U. Simonsson | Yanmin Hu | Oskar Clewe | Linda Aulin | Anthony R M Coates | L. Aulin | Oskar Clewe
[1] Yanmin Hu,et al. Targeting non-multiplying organisms as a way to develop novel antimicrobials. , 2008, Trends in pharmacological sciences.
[2] C. Dolea,et al. World Health Organization , 1949, International Organization.
[3] D. Mitchison,et al. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[4] M. Rajandream,et al. Regulation of hmp Gene Transcription inMycobacterium tuberculosis: Effects of Oxygen Limitation and Nitrosative and Oxidative Stress , 1999, Journal of bacteriology.
[5] C. Senner,et al. Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.
[6] D. Kell,et al. Formation and resuscitation of "non-culturable" cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. , 2002, Microbiology.
[7] Andrew C. Hooker,et al. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.
[8] A. Diacon,et al. The relationship between Mycobacterium tuberculosis MGIT time to positivity and cfu in sputum samples demonstrates changing bacterial phenotypes potentially reflecting the impact of chemotherapy on critical sub-populations. , 2015, The Journal of antimicrobial chemotherapy.
[9] R. Bax,et al. The future challenges facing the development of new antimicrobial drugs , 2002, Nature Reviews Drug Discovery.
[10] A. Lesse,et al. Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia , 2009, Antimicrobial Agents and Chemotherapy.
[11] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[12] P. Butcher,et al. Detection of mRNA Transcripts and Active Transcription in Persistent Mycobacterium tuberculosisInduced by Exposure to Rifampin or Pyrazinamide , 2000, Journal of bacteriology.
[13] L. G. Wayne. Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. , 2015, The American review of respiratory disease.
[14] B. Ngasala,et al. Population Pharmacokinetics and Pharmacodynamics of Artemether and Lumefantrine during Combination Treatment in Children with Uncomplicated Falciparum Malaria in Tanzania , 2010, Antimicrobial Agents and Chemotherapy.
[15] D B Kell,et al. A bacterial cytokine. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Vinks,et al. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.
[17] S. Gillespie,et al. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. , 2002, American journal of respiratory and critical care medicine.
[18] Mats O. Karlsson,et al. Handling Data Below the Limit of Quantification in Mixed Effect Models , 2009, The AAPS Journal.
[19] Yanmin Hu,et al. New Strategies for Antibacterial Drug Design , 2006 .
[20] Mats O. Karlsson,et al. Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.
[21] G. Maartens,et al. A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture , 2012, Antimicrobial Agents and Chemotherapy.
[22] Michael Nikolaou,et al. Modelling time-kill studies to discern the pharmacodynamics of meropenem. , 2005, The Journal of antimicrobial chemotherapy.
[23] R J Keizer,et al. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.
[24] L. G. Wayne. Dormancy ofMycobacterium tuberculosis and latency of disease , 1994, European Journal of Clinical Microbiology and Infectious Diseases.
[25] Arseny S Kaprelyants,et al. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. , 2011, Tuberculosis.
[26] O. Cars,et al. A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants. , 2015, The Journal of antimicrobial chemotherapy.
[27] Lena E. Friberg,et al. Pharmacokinetic/Pharmacodynamic (PK/PD) Indices of Antibiotics Predicted by a Semimechanistic PKPD Model: a Step toward Model-Based Dose Optimization , 2011, Antimicrobial Agents and Chemotherapy.
[28] M. Barer,et al. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. , 2010, American journal of respiratory and critical care medicine.
[29] S. Bhavnani,et al. Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. , 2011, Diagnostic microbiology and infectious disease.
[30] Ss Beal,et al. NONMEM User’s Guides. (1989–2009) , 2009 .
[31] A. Coates,et al. New strategies for antibacterial drug design: targeting non-multiplying latent bacteria. , 2006, Drugs in R&D.
[32] L. Gabbasova,et al. Global tuberculosis report (2014) , 2014 .
[33] M. Karlsson,et al. Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria , 2002, European Journal of Clinical Pharmacology.
[34] D. Mitchison,et al. Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[35] O. Cars,et al. A pharmacokinetic/pharmacodynamic model developed for the effect of colistin on Pseudomonas aeruginosa in vitro with evaluation of population pharmacokinetic variability on simulated bacterial killing. , 2014, The Journal of antimicrobial chemotherapy.
[36] L. Wayne,et al. Synchronized replication of Mycobacterium tuberculosis , 1977, Infection and immunity.
[37] Neang S. Ly,et al. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[38] Steven G. Woolfrey,et al. Analysis of Toxicokinetic Data Using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[39] D. Mitchison,et al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo , 2015, Front. Microbiol..
[40] Mats O. Karlsson,et al. Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model , 2002, Pharmaceutical Research.
[41] Hairong Huang,et al. Rifampin Stability in 7H9 Broth and Löwenstein-Jensen Medium , 2010, Journal of Clinical Microbiology.
[42] P. Butcher,et al. Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. , 1998, FEMS microbiology letters.
[43] L. Aarons,et al. Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.
[44] Michael Young,et al. Mutants of Mycobacterium tuberculosis Lacking Three of the Five rpf-Like Genes Are Defective for Growth In Vivo and for Resuscitation In Vitro , 2005, Infection and Immunity.
[45] G. Kaplan,et al. The resuscitation-promoting factors of Mycobacterium tuberculosis are required for virulence and resuscitation from dormancy but are collectively dispensable for growth in vitro , 2007, Molecular microbiology.
[46] D. Mitchison,et al. Persister populations of Mycobacterium tuberculosis in sputum that grow in liquid but not on solid culture media. , 2014, The Journal of antimicrobial chemotherapy.
[47] P. Andrew,et al. The in vivo environment accelerates generation of resuscitation-promoting factor-dependent mycobacteria. , 2014, American journal of respiratory and critical care medicine.